Journals / Kocaeli Tıp Dergisi / 2021 / Cilt: 10 - Sayı: 3

Management of Surgeries in Glanzmann Thrombastenia: Single Center Experience

Glanzmann Trombastenisinde Cerrahi Girişimlerin Yönetimi: Tek Merkez Deneyimi

Pages
252–260
Publication Date
2022-10-18
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Surgical procedures in patients with GT can be safely performed with collaboration of a hematologist by administering tranexamic acid, thrombocyte suspension and rVIIa.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:INTRODUCTION: Glanzmann thrombasthenia (GT) is a rare thrombocyte aggregation defect and there are no guidelines for supporting surgical hemostasis in patients with GT.
📊
Key Findings & Data:METHODS: In this retrospective study, patients with a diagnosis of GT, followed-up between 1999 and 2000 and underwent surgical procedure were analyzed.
💡
Conclusion & Impact:Surgical procedures in patients with GT can be safely performed with collaboration of a hematologist by administering tranexamic acid, thrombocyte suspension and rVIIa.
🔬Design:Research Article
📍Scope:2000 Verileri
⚙️Variables:Domain Parameters

Abstract

INTRODUCTION: Glanzmann thrombasthenia (GT) is a rare thrombocyte aggregation defect and there are no guidelines for supporting surgical hemostasis in patients with GT. The aim of the present study is to share the experiences in bleeding control of surgical interventions of patients with GT. METHODS: In this retrospective study, patients with a diagnosis of GT, followed-up between 1999 and 2000 and underwent surgical procedure were analyzed. Patients’ age at diagnosis, bleeding characteristics, surgical procedures, hemostatic treatments, and bleeding complications of surgery were analyzed. RESULTS: Twenty-three surgical procedures were performed in 13 patients. Thirteen (56.5%) of these procedures were tooth extractions. Thrombocyte concentrate, and oral tranexamic acid were started before tooth extractions and oral treatment was continued for 5 days but in three of these procedures bleeding control was poor after the procedure. In two of these procedures, bleeding was controlled with recombinant factor VIIa (rFVIIa). In bronchoscopy, varicocele, circumcision, thyroglosal cyst operations and molar tooth extractions, rFVIIa was used alone or in addition and bleeding control was achieved. In four patients with history of surgical interventions performed before GT diagnosis, bleeding complications were reported whereas bleeding control was good in a cesarean operation performed without any hemostatic agent. DISCUSSION AND CONCLUSION: Patients with suspected bleeding defect or with bleeding defect must be referred to the hematologist. Abnormal platelet clumping in peripheral smear performed from the fingertip, prolonged bleeding time suggest GT. Surgical procedures in patients with GT can be safely performed with collaboration of a hematologist by administering tranexamic acid, thrombocyte suspension and rVIIa.

Özet

GİRİŞ ve AMAÇ: Glanzmann trombastenisi (GT) nadir görülen trombosit agregasyon kusurudur ve GT tanılı hastaların cerrahi girişimlerinde uygulanacak hemostaz desteği ile ilgili rehberler bulunmamaktadır. Bu çalışmada GT tanısı ile takip edilen hastalarda uygulanan cerrahi girişimlerde kanama kontrolü ile ilgili deneyimlerin paylaşılması amaçlandı. YÖNTEM ve GEREÇLER: 13 Geriye dönük yapılan bu çalışmada 1999-2020 yılları arasında GT tanısı alarak izlenen hastalara uygulanan cerrahi işlemler değerlendirildi Hastaların tanı yaşları, kanama şekilleri, hastalara uygulanan cerrahi işlemler ve cerrahi işlemlerde uygulanan tedaviler ile cerrahi ilişkili kanamalar incelendi. BULGULAR: Çalışmada 13 hastaya, 23 cerrahi işlem uygulandı. İşlemlerin 13’ü (%56,5) diş çekimiydi. Tanısı bilinen hastaların diş çekimlerinde, işlem öncesi trombosit süspansiyonu ve oral traneksamik asit başlandı, oral tedavi 5 gün sürdürüldü. Bronkoskopi, varikosel, sünnet, tiroglosal kist operasyonu ve azı dişi çekimlerinde ise bu tedavilere ilave olarak veya tek başına rekombinant Faktör VIIa (rFVIIa) kullanıldı ve kanama kontrolü sağlandı. Üç hastanın diş çekimi öncesi traneksamit asit ve trombosit süspansiyonu verilmesine karşın işlem sonrasında kanama gözlendi. Bu işlemlerin ikisinde rFVIIa da tedaviye eklenerek kanama kontrolü sağlandı. Tanı öncesi, herhangi bir hemostatik ajan verilmeden cerrahi girişim uygulandığı belirtilen dört hastada kanama komplikasyonu geliştiği; bir hastada ise hemostatik ajan verilmemesine karşın sezaryen operasyonunda kanama kontrolünün iyi olduğu öğrenildi. TARTIŞMA ve SONUÇ: Kanama açısından şüpheli öyküsü olan veya kanama kusuru saptanmış hastalar cerrahi öncesi hematoloji uzmanına yönlendirilmelidir. Parmak ucundan yapılacak periferik yaymada trombosit kümelenmesinin görülmemesi ve kanama zamanının uzun olması GT tanısına yönlendirir. GT tanılı hastalarda cerrahi işlemler hematoloji uzmanı iş birliğiyle, traneksamik asit, trombosit süspansiyonu ve rFVIIa uygulanarak güvenle yapılabilir.

🔖

Cite This Article

Sarper, N., Gelen, S. A. (2022). Management of Surgeries in Glanzmann Thrombastenia: Single Center Experience. Kocaeli Tıp Dergisi, Cilt: 10 - Sayı: 3, 252–260. https://ajindex.com/articles/574703

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (6)

  1. Bellucci S, Caen J. Molecular basis of Glanzmann's Thrombasthenia and current strategies in treatment. Blood Rev. 2002;16(3):193-202
  2. George JN, Caen JP, Nurden AT. Glanzmann's thrombasthenia: the spectrum of clinical disease. Blood. 1990;75(7):1383-95
  3. Toogeh G, Sharifian R, Lak M, Safaee R, Artoni A, Peyvandi F. Presentation and pattern of symptoms in 382 patients with Glanzmann thrombasthenia in Iran. Am J Hematol. 2004;77(2):198-9
  4. Poon MC, Di Minno G, d'Oiron R, Zotz R. New Insights Into the Treatment of Glanzmann Thrombasthenia. Transfus Med Rev. 2016 Apr;30(2):92-9
  5. Tarawah A, Owaidah T, Al-Mulla N, Khanani MF, Elhazmi J, Albagshi M, et al. Management of Glanzmann's Thrombasthenia – Guidelines based on an expert panel consensus from gulf cooperation council countries. J Appl Hematol 2019;10:1-9. 6.Fiore M, Firah N, Pillois X, Nurden P, Heilig R, Nurden AT. Natural history of platelet antibody formation against aIIbß3 in a French cohort of Glanzmann thrombasthenia patients. Haemophilia. 2012;18(3):201-9. 7.Di Minno G, Zotz RB, d'Oiron R, Bindslev N, Di Minno MN, Poon MC; Glanzmann Thrombasthenia Registry Investigators. The international, prospective Glanzmann Thrombasthenia Registry: treatment modalities and outcomes of non-surgical bleeding episodes in patients with Glanzmann thrombasthenia. Haematologica. 2015 Aug;100(8):1031-7. 8.Bolton‑Maggs PH, Chalmers EA, Collins PW, Harrison P,Kitchen S, Liesner RJ, et al. A review of inherited platelet disorders with guidelines for their management on behalf of the UKHCDO. Br J Haematol 2006;135:603‑33. 9.Hayward CP, Rao AK, Cattaneo M. Congenital platelet disorders:Overview of their mechanisms, diagnostic evaluation and treatment. Haemophilia 2006;12 Suppl 3:128‑36. 10.Italian Society for the Study of Hemostasis and Thrombosis. Treatment of bleeding and preparation for maneuvers Invasive In Patients with Platelet Disease and / or Platelet Hereditary or Acquired. Available from: http://www.siset.org/lineeguida/ LG4.pdf. [Last accessed on 2019 Mar 31]. 11.Sebastiano C, Bromberg M, Breen K, Hurford MT. Glanzmann’s thrombasthenia: report of a case and review of the literature. Int J Clin Exp Pathol 2010;25;443-7. 12.Grainger JD, Thachil J, Will AM. How we treat the platelet glycoprotein defects; Glanzmann thrombasthenia and Bernard Soulier syndrome in children and adults. Br J Haematol. 2018 Sep;182(5):621-32
  6. Zotz RB, Poon MC, Di Minno G, D'Oiron R; Glanzmann Thrombasthenia Registry Investig